Augmented Reality

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Feb 5, 2026

Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 Broomfield, CO, February 5, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Jan 13, 2026

Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million...

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Jan 6, 2026

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion,...

Aclarion Appoints Greg Gould as Chief Financial Officer

Sep 3, 2025

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is...

Gen Z, AR, and E-Commerce: Value, Barriers, and Behavior

Jul 21, 2025

Augmented Reality in E-Commerce and Gen Z Consumer Behavior New York, July 21, 2025 - PRISM MediaWire https://youtu.be/zFF6ZXLEOxE Summary Augmented Reality (AR) is rapidly transforming e-commerce by offering immersive shopping experiences that address critical issues, such as high product return rates and consumer decision ambiguity. However, despite its potential, widespread adoption of AR faces challenges related to consumer psychological barriers. This study, focusing on Gen Z consumers (a...

Vibe Coding: The Future of Industrial Programming (2025-2030)

Jul 17, 2025

• Vibe coding transformed from intuitive to AI-augmented, becoming a collaborative human-AI process driven by LLMs. Natural language is now the primary programming interface, shifting developers' roles to "AI conductors" focusing on high-level guidance and evaluation. • AI-assisted vibe coding & LCNC offer accelerated development, cost reduction, and democratization. However, they introduce critical challenges: inconsistent code quality, heightened security vulnerabilities (due to...

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 20, 2025

USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 - PRISM MediaWire - Aclarion, Inc.,...

NEWSROOM

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Aclarion Appoints Greg Gould as Chief Financial Officer

Gen Z, AR, and E-Commerce: Value, Barriers, and Behavior

Vibe Coding: The Future of Industrial Programming (2025-2030)

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Contact Us